Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC).

• Authors: ARDIZZONI Andrea; RAZIS Evangelia; LICHINITSER Mikhail; YILMAZ Ugur; GRIGORESCU Alexandru; MORERO Jusé Luis; SKŘIČKOVÁ Jana; CERVANTES Guadalupe; GOTTFRIED Maya; VAN MEERBEECK Jan
• Year of publication: 2007
• Type: Article in Proceedings
• Conference: Journal of Thoracic Oncology
• MU Faculty or unit: Faculty of Medicine
• Field: Oncology and hematology
• Keywords: Erlotinib; non-small cell lung cancer; drug safety; TRUST study
• Description: An international group of authors have published interim results concerning the drug safety of erlotinib, an anti-tumor drug used in treatment of patients with advanced non-small cell lung cancer within TRUST, a global open-label study of erlotinib.

Related projects

• Environment - carcinogenesis - oncology